

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
New Rheogene I, LLC	07/30/2003
RECEIVING PARTY DATA	
Name:	University of Pittsburgh Medical Center
Street Address:	200 Lothrop Street
City:	Pittsburgh
State/Country:	PENNSYLVANIA
Postal Code:	15213
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	10490976
Application Number:	10787906
Application Number:	10783810
Application Number:	10490971
CORRESPONDENCE DATA	
Fax Number:	(412)209-1845
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>
Phone:	4122974731
Email:	jmartinez@cohenlaw.com
Correspondent Name:	Cohen & Grigsby, P.C.
Address Line 1:	11 Stanwix Street
Address Line 2:	15th Floor
Address Line 4:	Pittsburgh, PENNSYLVANIA 15222-1319
ATTORNEY DOCKET NUMBER:	10271.1INTREXON
NAME OF SUBMITTER:	Jennifer L. Martinez

CH \$160.00 10490976

Total Attachments: 8

source=3NewRheogenetoUPMCAssignment#page1.tif

source=3NewRheogenetoUPMCAssignment#page2.tif

source=3NewRheogenetoUPMCAssignment#page3.tif

source=3NewRheogenetoUPMCAssignment#page4.tif

source=3NewRheogenetoUPMCAssignment#page5.tif

source=3NewRheogenetoUPMCAssignment#page6.tif

source=3NewRheogenetoUPMCAssignment#page7.tif

source=3NewRheogenetoUPMCAssignment#page8.tif

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT OF PATENTS is entered into as of July 30, 2003 (the "Effective Date") by and between New RheoGene I, LLC, a Delaware limited company (the "Assignor"), and the University of Pittsburgh Medical Center, a Pennsylvania nonprofit corporation ("UPMC").

RECITALS

- A. The Assignor has adopted, used and is using and owns all right, title and interest in and to the patents and applications for patents identified and set forth on Exhibit A attached hereto (collectively, the "Patents"), and the goodwill of the business associated with the Patents.
- B. Each of the Assignor, New RheoGene II, LLC and UPMC have entered into that certain Asset Distribution Agreement dated as of July 30, 2003 (the "Distribution Agreement"). Capitalized terms used herein without definition shall have the respective meanings given to them in the Distribution Agreement.
- C. Pursuant to the Distribution Agreement, the Assignor has agreed to assign to UPMC its entire right, title and interest in and to the Patents.
- D. Pursuant to the Distribution Agreement, the Assignor wishes to assign the Patents to UPMC, and UPMC wishes to accept such assignment, on the terms and conditions set forth herein.

AGREEMENT


The parties, intending to be legally bound, agree as follows:

1. **Assignment of Patents.**
 - (a) The Assignor hereby, assigns and transfers all of its right, title and interest in and to the Patents to UPMC, its successors and assigns, to be held and enjoyed by UPMC for its use, enjoyment or conveyance, together with the goodwill of the business symbolized by the Patents.
 - (b) The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks for the jurisdictions listed on Exhibit A with respect to each Patent, or such other appropriate official with respect to such jurisdiction, to record UPMC as the owner of, and to issue in accordance with this instrument, each of the Patents in the name of the UPMC.
2. **Successors and Assigns.** This Assignment of Patents shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns.
3. **Choice of Law.** This Assignment of Patents shall be construed in accordance with, and governed in all respects by, the internal laws of the Commonwealth of Pennsylvania without reference to conflict of laws principles.
4. **Counterparts.** This Assignment of Patents may be signed in one or more counterparts, each of which shall be deemed an original and together which shall constitute one and the same instrument.

4. **Counterparts.** This Assignment of Patents may be signed in one or more counterparts, each of which shall be deemed an original and together which shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed and delivered this Assignment of Patents as of the date first written above.

NEW RHEOGENE I, LLC

By: 
Name: Thomas Tillett
Title: CEO

UNIVERSITY OF PITTSBURGH MEDICAL CENTER

By: _____
Name: _____
Title: _____


4. **Counterparts.** This Assignment of Patents may be signed in one or more counterparts, each of which shall be deemed an original and together which shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed and delivered this Assignment of Patents as of the date first written above.

NEW RHEOGENE I, LLC

By: _____
Name: _____
Title: _____


UNIVERSITY OF PITTSBURGH MEDICAL
CENTER

By:  _____
Name: SCOTT M LAMMIE
Title: SVP - FINANCE

COMMONWEALTH OF PENNSYLVANIA)
) SS:
COUNTY OF ALLEGHENY)

Before me, a Notary Public in and for said County and Commonwealth personally appeared SCOTT M LAMMIE, SUP FINANCE of UARC, known to be or satisfactorily proven to be the person and officer whose name was subscribed to the within Assignment of Patents, and acknowledged that he executed the same on behalf of UARC, as his voluntary act and deed for the purposes and consideration therein expressed and in the capacity therein given.

Therefore, I have set my hand and affixed my official seal on July 30, 2003.



Notary Public

(Seal)

Notarial Seal
Peggy J. Haberie, Notary Public
City of Pittsburgh, Allegheny County
My Commission Expires Aug. 22, 2005
Member, Pennsylvania Association of Notaries

COMMONWEALTH OF PENNSYLVANIA)

COUNTY OF MONTGOMERY)

SS:

Before me, a Notary Public in and for said County and Commonwealth personally appeared Thomas Tillet Ambler of Pennsylvania, known to be or satisfactorily proven to be the person and officer whose name was subscribed to the within Assignment of Patents, and acknowledged that he executed the same on behalf of Newkirk I, as his voluntary act and deed for the purposes and consideration therein expressed and in the capacity therein given.

Therefore, I have set my hand and affixed my official seal on July 30, 2003.

Judanne McCoy
Notary Public
(Seal) *July 30, 2003*

Notarial Seal
Judanne McCoy, Notary Public
Lower Providence Twp., Montgomery County
My Commission Expires Sept. 1, 2003
Member, Pennsylvania Association of Notaries

EXHIBIT A

Patent and Patent Applications

Docket #	Patent/Serial #	Date Filed	Issue Date	Title
98-039A	AR 990102851	06/15/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	AU 9933900	06/07/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	BR 99022834	06/16/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	CN 991090675	6/17/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	EP 99304444.5	06/08/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	JP 99171358	06/17/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	KR 9922745	06/17/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	MX 995570	06/16/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	TW 88110230	06/17/99	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039A	US 6258603	05/20/99	7/10/01	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
98-039B	US 09/832500	04/11/01	pending	Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
A01020	US 60/191355	03/22/00	expired	Heterodimeric and Homodimeric Nuclear Receptor Gene Switches
A01020A	PCT/US01/09050	03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A01020A	AR 010101339	03/22/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A01020A	CL 6422001	03/22/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A01020A	TW 90106737	03/22/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A0120A	US 10/239134	03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A0120A	AU	03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A0120A	CA 2404253	03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A0120A	CN 01807844.3	03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A0120A	JP 2001569016	03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A0120A	MX PA/A/2002/00915	03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A0120A		03/21/01	pending	Novel Ecdysone Receptor-Based Inducible Gene Expression System
A01020B	US	09/26/01	pending	Novel Ecdysone Receptor-Based Inducible Gene

	09/965,703				Expression System
A01121	US 09/690391	10/17/00	pending		Methods for Identifying Products Employing Gene Expression
A01121	AU 0178282	10/09/01	pending		Methods for Identifying Products Employing Gene Expression
A01121	BR 01045350	10/16/01	pending		Methods for Identifying Products Employing Gene Expression
A01121	CN 011358009	10/17/01	pending		Methods for Identifying Products Employing Gene Expression
A01121	EP 10308598.0	10/09/01	pending		Methods for Identifying Products Employing Gene Expression
A01121	JP-2001319364	10/17/01	pending		Methods for Identifying Products Employing Gene Expression
A01121	KR 2001163782	10/16/03	pending		Methods for Identifying Products Employing Gene Expression
A01121	MX 2001010284	10/11/01	pending		Methods for Identifying Products Employing Gene Expression
A01121	TW 90125676	10/17/01	pending		Methods for Identifying Products Employing Gene Expression
A01121A	US 09/950312	09/10/01	pending		Methods for Identifying Products Employing Gene Expression
A01121	US 60/269799	02/20/01	expired		Novel Ecdysone Receptor-Based Inducible Gene Expression Systems
A01183	US 60260700	01/10/01	expired		A Method to Reduce Transcriptional Interference Between Tandem Genes
A01183	US 10074744	02/13/02	pending		A Method to Reduce Transcriptional Interference Between Tandem Genes
A01184	US 60/294814	05/31/01	pending		Novel Ecdysone Receptor/Invertebrate Retinoid X Receptor-Based Inducible Gene Expression System
A01237	PCT/US02/0 5235	02/20/02	pending		Novel Ecdysone Receptor/Invertebrate Retinoid X Receptor-Based Inducible Gene Expression System
A01238	US 60/294819	05/31/01	expired		Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
A01238	PCT/US02/0 5706	02/20/02	pending		Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
A01258	US 60/301301	06/27/01	expired		A Method to Determine Gene Function
A01248	US 60/325534	09/26/01	expired		Whitefly Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof
A01248	PCT/US02/0 5234	02/20/02	pending		Whitefly Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof
A01284	US 60/325096	09/26/01	expired		Leafhopper Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof
A01284	PCT/US02/0 5026	02/20/02	pending		Leafhopper Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof
A01310	US 60/329211	10/12/01	pending		Systems for Site Specific Alteration of Genomes
A01282	US 60/342,614	12/20/01	pending		In Vitro Biosensor Composition Containing a Ligand-Dependent Nuclear Receptor Ligand Binding Domain
A01282A	US 60/342639	12/20/01	pending		In Vitro Biosensor Composition Containing a Ligand-Dependent Nuclear Receptor Ligand Binding Domain
A01308	US 60/348427	01/14/02	pending		Minimal DNA Binding Domain Polynucleotides, Polypeptides, and Uses Thereof
A01381	US 60/466,233	02/10/03	pending		Diacylhydrazine ligands for modulating the expression

PATENT

				of exogenous genes in mammalian systems via an ecdysone receptor complex
A01494	US 60/449,467	02/21/03	pending	Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
A01500	US 60/451,124	02/28/03	pending	Fluxinal boron-containing diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex